Trials / Completed
CompletedNCT00426218
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 4 Years – 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, open label, repeated dose, range finding study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and efficacy of ACZ885, a fully human anti-interleukin-1B (anti-IL-1B) monoclonal antibody, given subcutaneously in pediatric subjects with active SJIA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-03-01
- First posted
- 2007-01-24
- Last updated
- 2011-08-09
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00426218. Inclusion in this directory is not an endorsement.